The effects on Tau pathology were assessed by immunohistochemistry, qPCR, and behavioral assays.<h4>Results</h4>Using 2H2D11, the newly developed antibody specifically targeting the AcMet11-Tau variant, we demonstrated that this species accumulated early in degenerating neurons in both transgenic mouse models of AD-related Tau pathology and post-mortem brain tissues from AD patients. This evidence concerns the gene MAPT and Alzheimer disease.